Xellia Pharmaceuticals
Budget
€200 — €0
EP Access
0
accredited persons
Staff
4
0.4 FTE
EU Grants
None
Mission & Goals
Xellia Pharmaceuticals is the global leader in fermentation-based non-beta-lactam anti-infectives. We manufacture and supply APIs as well as Finished Dosage Forms (FDFs) to over 500 pharmaceutical companies across 80 countries. The World Health Organization and the European Union recognize a variety of our products as essential and critical medicines, serving as crucial resources in the fight against severe infections and antimicrobial resistance. Headquartered in Copenhagen, Denmark, Xellia Pharmaceuticals boasts a global footprint, with manufacturing sites in Denmark, Hungary, and China, alongside R&D and commercial operations in an additional eight locations around the world. We stand as the sole European manufacturer of several of our products and possess a rich legacy of over 120 years in the pharmaceutical industry.
EU Legislative Interests
Critical Medicines Act
Communication Activities
https://www.xellia.com/news/xellia-announces-multiyear-plans-to-phase-out-copenhagen-site-in-strategic-shift https://www.alpbach.org/uploads/Alpbach-Communique%CC%81-Antibiotics-Resolution-Notes-v29-08-Sep-2025.pdf
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Critical Medicines Alliance Danish Industry https://www.xellia.com/
Organisation Members
https://www.xellia.com/
Commissioner Meetings
No recorded meetings with EU commissioners.